Q-omics provides the consensus-scored KCNB2 profile across patient tissues and cancer cell-line models. KCNB2 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in DLBC. Among the 18 cancer types available for tumor–normal comparison, KCNB2 is differentially expressed in 12, with the highest sampling consensus in KIRC. Additionally, KCNB2 RNA expression shows 13,733 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight DLBC, KIRC, and TGCT as cancer lineages where KCNB2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for KCNB2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes KCNB2 survival associations across molecular data types. KCNB2 RNA expression shows survival associations in the most cancer types (23), followed by mutation status (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible KCNB2 RNA expression–survival associations across cancer types. High KCNB2 expression shows unfavorable associations in DLBC, UVM, OV and UCEC, but favorable associations in LUAD and PAAD. The DLBC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify DLBC as the clearest survival context for KCNB2 RNA expression.
This table summarizes KCNB2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for KCNB2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. KCNB2 shows lower tumor expression in KIRC, COAD, BRCA, KICH and UCEC and higher tumor expression in LUSC. The KIRC box plot shows higher KCNB2 RNA expression in normal versus tumor tissue (log2 FC = −0.172, t-test p < 0.001).
This table shows molecular features associated with KCNB2 in patient tissues and cancer cell lines. In patient samples, KCNB2 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, KCNB2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in URINARY_TRACT, while CRISPR and shRNA rows add functional-dependency signals in LIVER and LARGE_INTESTINE.
